NLRP3 and Patent ductus arteriosus: In summary, the results of this study suggest that XLOC_000647 not only acts as a new tumor-inhibiting factor of lncRNA, but also may be regarded as a major adjustment factor of NLRP3, which is able to inhibit cell proliferation, invasion, and EMT of PDA.